Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- EFPIA Japan Issues Statement on Vaccination System under COVID-19 Crisis, Calls for Eliminating Obstacles for Vaccine Imports
September 14, 2020
- JPMA to Commit to Growth of Research-Driven Pharma Industry, R&D of COVID-19 Drugs, Vaccines: Director General
September 7, 2020
- Generic APIs at Crossroads - 2: Traders’ Group Urges Simpler Regulatory Procedures to Facilitate API Substitution
August 13, 2020
- JMA’s New Pharma Affairs Exec Wants More Stringent Rules on Sakigake, Conditional Approval
August 11, 2020
- Bayer Yakuhin President Heike Prinz Elected New EFPIA Japan Chief
August 3, 2020
- Japan Ob-Gyn Society Lauds Approval of 9-Valent HPV Vaccine, Plaintiffs Renew Protest
July 27, 2020
- Pharmacist Group Says Drug Price Survey This Year “Utterly Unacceptable”
July 21, 2020
- Expand Self-Medication Tax Break and Make It Permanent: Industry Groups
July 20, 2020
- Trade Group Urges Drug Makers to Fully Provide Info on Stock-Outs, Supply Curbs
July 20, 2020
- JPMA Reiterates It’s Not the Right Time for Off-Year Drug Price Survey
July 17, 2020
- Number of Contract Sales Reps Up 10.8% to 3,445, with New Drug Launches
July 17, 2020
- JMA Chief Says Off-Year Price Survey “Technically Impossible”, JPA President Meets PM
July 16, 2020
- Japan Red Cross Presses ahead with Joint Purchase of Drugs Selected under Formularies at Group Hospitals
July 15, 2020
- AMR Action Fund Would Help Deal with Threat While We Still Have Time: IFPMA Vice Pres.
July 14, 2020
- JMA Reiterates Concerns for Off-Year Drug Price Survey after Govt’s Honebuto Draft Revealed
July 13, 2020
- Mobile Pharmacy Van Set in Motion as Kumamoto Downpour Hits Local Stores, Some Wholesalers
July 8, 2020
- Wholesaler Group Makes Emergency Plea against Off-Year Drug Price Survey
July 7, 2020
- Expand Self-Medication Tax Break to Cover All Non-Prescription Drugs: OTC Group
July 6, 2020
- Stop Patient Enrollment in Avigan Studies: Drug Damage Watchdog
July 3, 2020
- Drug Makers Joining Forces to Share Manufacturing Capacities, Accelerate COVID-19 Programs: PhRMA CMO
July 2, 2020
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…